Gene therapy strategies for cardiac electrical dysfunction

Journal of Molecular and Cellular Cardiology

Volumn 50, Issue 5, 2011, Pages 759-765

  Greener, Ian ^a   Donahue, J Kevin ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Arrhythmia; Gene therapy; Myocardium

Indexed keywords

ADENOVIRUS VECTOR; BETA 2 ADRENERGIC RECEPTOR; CLARITHROMYCIN; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR2.1; LENTIVIRUS VECTOR; MICRORNA; MICRORNA 1; POTASSIUM CHANNEL; POTASSIUM CHANNEL KCNH2; POTASSIUM CHANNEL KV1.5; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 2A; SKELETAL MUSCLE SODIUM CHANNEL ISOFORM; SODIUM CHANNEL NAV1.5; UNCLASSIFIED DRUG;

BRADYCARDIA; CARDIOVASCULAR RESPONSE; CELL THERAPY; DRUG EFFICACY; FIBROBLAST; GENE EXPRESSION; GENE MUTATION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; HEART ATRIUM ARRHYTHMIA; HEART DISEASE; HEART ELECTROPHYSIOLOGY; HEART INFARCTION; HEART VENTRICLE ARRHYTHMIA; HUMAN; MEMBRANE POTENTIAL; NONHUMAN; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; VIRAL GENE DELIVERY SYSTEM;

ARRHYTHMIAS, CARDIAC; ATRIAL FIBRILLATION; BRADYCARDIA; GENE THERAPY; HUMANS;

EID: 79953681886     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2010.07.022     Document Type: Review

References (45)

1. Fox C.S., Evans J.C., Larson M.G., Kannel W.B., Levy D. Temporal trends in coronary heart disease mortality and sudden cardiac death from 1950 to 1999: the Framingham Heart Study. Circulation 2004, 110:522-527.
2. Echt D.S., Liebson P.R., Mitchell L.B., Peters R.W., Obias-Manno D., Barker A.H., et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N. Engl. J. Med. 1991, 324:781-788.
3. Lipskaia L., Chemaly E.R., Hadri L., Lompre A.M., Hajjar R.J. Sarcoplasmic reticulum Ca(2+) ATPase as a therapeutic target for heart failure. Expert. Opin. Biol. Ther. 2010, 10:29-41.
4. Kikuchi K., McDonald A.D., Sasano T., Donahue J.K. Targeted modification of atrial electrophysiology by homogeneous transmural atrial gene transfer. Circulation 2005, 111:264-270.
5. Sasano T., Kikuchi K., McDonald A.D., Lai S., Donahue J.K. Targeted high-efficiency, homogeneous myocardial gene transfer. J. Mol. Cell Cardiol. 2007, 42:954-961.
6. Nattel S., Maguy A., Le B.S., Yeh Y.H. Arrhythmogenic ion-channel remodeling in the heart: heart failure, myocardial infarction, and atrial fibrillation. Physiol. Rev. 2007, 87:425-456.
7. Lin H., Parmacek M., Morle G., Bolling S., Leiden J. Expression of recombinant genes in the myocardium in vivo after direct injection of DNA. Circulation 1990, 82:2217-2221.
8. Shenk T. Adenoviridae: the viruses and their replication. Fields of Virology 2010, 2111-2148. Lippincott-Raven Publishers, Philadelphia. 3rd ed.
9. Ferrari F.K., Samulski T., Shenk T., Samulski R.J. Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J. Virol. 1996, 70:3227-3234.
10. Hauck B., Zhao W., High K., Xiao W. Intracellular viral processing, not single-stranded DNA accumulation, is crucial for recombinant adeno-associated virus transduction. J. Virol. 2004, 78:13678-13686.
11. High K., Tigges M., Manno C., Sabatino D., Arruda V., Herzog R., et al. Human immune responses to AAV-2 capsid may limit duration of expression in liver-directed gene transfer in humans with hemophilia B. Blood 2004, 104:413.
12. Cleghorn F.R., Reitz M.S., Popovic M., et al. Human immunodeficiency viruses. Principles and Practice of Infectious Diseases 2010, 2119-2130. G.L. Mandell, J.E. Bennett, R. Dolin (Eds.).
13. Bonci D., Cittadini A., Latronico M.V., Borello U., Aycock J.K., Drusco A., et al. 'Advanced' generation lentiviruses as efficient vectors for cardiomyocyte gene transduction in vitro and in vivo. Gene Ther. 2003, 10:630-636.
14. Cockrell A.S., Kafri T. Gene delivery by lentivirus vectors. Mol. Biotechnol. 2007, 36:184-204.
15. Lundstrom K. Latest development in viral vectors for gene therapy. Trends Biotechnol. 2003, 21:117-122.
16. Gregorevic P., Blankinship M., Allen J., Crawford R., Meuse L., Miller D., et al. Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat. Med. 2004, 10:828-834.
17. Kass-Eisler A., Falck-Pedersen E., Alvira M., Rivera J., Buttrick P.M., Wittenberg B.A., et al. Quantitative determination of adenovirus-mediated gene delivery to rat cardiac myocytes in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A 1993, 90:11498-11502.
18. Benjamin E.J., Wolf P.A., D'Agostino R.B., Silbershatz H., Kannel W.B., Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998, 98:946-952.
19. Amit G., Kikuchi K., Greener I.D., Yang L., Novack V., Donahue J.K. Selective Molecular Potassium Channel Blockade Prevents Atrial Fibrillation. Circulation 2010.
20. Curran M.E., Splawski I., Timothy K.W., Vincent G.M., Green E.D., Keating M.T. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995, 80:795-803.
21. Burton D.Y., Song C., Fishbein I., Hazelwood S., Li Q., DeFelice S., et al. The incorporation of an ion channel gene mutation associated with the long QT syndrome (Q9E-hMiRP1) in a plasmid vector for site-specific arrhythmia gene therapy: in vitro and in vivo feasibility studies. Hum. Gene Ther. 2003, 14:907-922.
22. Abbott G.W., Sesti F., Splawski I., Buck M.E., Lehmann M.H., Timothy K.W., et al. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 1999, 97:175-187.
23. Donahue J.K., Heldman A.W., Fraser H., McDonald A.D., Miller J.M., Rade J.J., et al. Focal modification of electrical conduction in the heart by viral gene transfer. Nat. Med. 2000, 6:1395-1398.
24. Bauer A., McDonald A.D., Nasir K., Peller L., Rade J.J., Miller J.M., et al. Inhibitory G protein overexpression provides physiologically relevant heart rate control in persistent atrial fibrillation. Circulation 2004, 110:3115-3120.
25. Bunch T.J., Mahapatra S., Bruce G.K., Johnson S.B., Miller D.V., Horne B.D., et al. Impact of transforming growth factor-beta1 on atrioventricular node conduction modification by injected autologous fibroblasts in the canine heart. Circulation 2006, 113:2485-2494.
26. Rosenbaum D.S., Jackson L.E., Smith J.M., Garan H., Ruskin J.N., Cohen R.J. Electrical alternans and vulnerability to ventricular arrhythmias. N. Engl. J. Med. 1994, 330:235-241.
27. Cutler M.J., Wan X., Laurita K.R., Hajjar R.J., Rosenbaum D.S. Targeted SERCA2a gene expression identifies molecular mechanism and therapeutic target for arrhythmogenic cardiac alternans. Circ. Arrhythm. Electrophysiol. 2009, 2:686-694.
28. Peters N.S., Coromilas J., Severs N.J., Wit A.L. Disturbed connexin43 gap junction distribution correlates with the location of reentrant circuits in the epicardial border zone of healing canine infarcts that cause ventricular tachycardia. Circulation 1997, 95:988-996.
29. Lau D.H., Clausen C., Sosunov E.A., Shlapakova I.N., Anyukhovsky E.P., Danilo P., et al. Epicardial border zone overexpression of skeletal muscle sodium channel SkM1 normalizes activation, preserves conduction, and suppresses ventricular arrhythmia: an in silico, in vivo, in vitro study. Circulation 2009, 119:19-27.
30. Yang B., Lin H., Xiao J., Lu Y., Luo X., Li B., et al. The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat. Med. 2007, 13:486-491.
31. Fishbein M.C., Maclean D., Maroko P.R. Experimental myocardial infarction in the rat: qualitative and quantitative changes during pathologic evolution. Am. J. Pathol. 1978, 90:57-70.
32. Sasano T., McDonald A.D., Kikuchi K., Donahue J.K. Molecular ablation of ventricular tachycardia after myocardial infarction. Nat. Med. 2006, 12:1256-1258.
33. Brunner M., Kodirov S.A., Mitchell G.F., Buckett P.D., Shibata K., Folco E.J., et al. In vivo gene transfer of Kv1.5 normalizes action potential duration and shortens QT interval in mice with long QT phenotype. Am. J. Physiol. Heart Circ. Physiol. 2003, 285:H194-H203.
34. Kodirov S.A., Brunner M., Busconi L., Koren G. Long-term restitution of 4-aminopyridine-sensitive currents in Kv1DN ventricular myocytes using adeno-associated virus-mediated delivery of Kv1.5. FEBS Lett. 2003, 550:74-78.
35. Edelberg J.M., Aird W.C., Rosenberg R.D. Enhancement of murine cardiac chronotropy by the molecular transfer of the human beta2 adrenergic receptor cDNA. J. Clin. Invest. 1998, 101:337-343.
36. Miake J., Marban E., Nuss H.B. Biological pacemaker created by gene transfer. Nature 2002, 419:132-133.
37. Qu J., Plotnikov A.N., Danilo P., Shlapakova I., Cohen I.S., Robinson R.B., et al. Expression and function of a biological pacemaker in canine heart. Circulation 2003, 107:1106-1109.
38. Plotnikov A.N., Sosunov E.A., Qu J., Shlapakova I.N., Anyukhovsky E.P., Liu L., et al. Biological pacemaker implanted in canine left bundle branch provides ventricular escape rhythms that have physiologically acceptable rates. Circulation 2004, 109:506-512.
39. Tse H.F., Xue T., Lau C.P., Siu C.W., Wang K., Zhang Q.Y., et al. Bioartificial sinus node constructed via in vivo gene transfer of an engineered pacemaker HCN Channel reduces the dependence on electronic pacemaker in a sick-sinus syndrome model. Circulation 2006, 114:1000-1011.
40. Plotnikov A.N., Shlapakova I., Szabolcs M.J., Danilo P., Lorell B.H., Potapova I.A., et al. Xenografted adult human mesenchymal stem cells provide a platform for sustained biological pacemaker function in canine heart. Circulation 2007, 116:706-713.
41. Kahlig K.M., Saridey S.K., Kaja A., Daniels M.A., George A.L., Wilson M.H. Multiplexed transposon-mediated stable gene transfer in human cells. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:1343-1348.
42. Ying Y., Muller O.J., Goehringer C., Leuchs B., Trepel M., Katus H.A., et al. Heart-targeted adeno-associated viral vectors selected by in vivo biopanning of a random viral display peptide library. Gene Ther. 2010.
43. Cartier N., Hacein-Bey-Abina S., Bartholomae C.C., Veres G., Schmidt M., Kutschera I., et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009, 326:818-823.
44. Aiuti A., Cattaneo F., Galimberti S., Benninghoff U., Cassani B., Callegaro L., et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N. Engl. J. Med. 2009, 360:447-458.
45. Bainbridge J.W., Smith A.J., Barker S.S., Robbie S., Henderson R., Balaggan K., et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N. Engl. J. Med. 2008, 358:2231-2239.